Andrew Balo

2018

In 2018, Andrew Balo earned a total compensation of $3.2M as EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development at DexCom, a 5% increase compared to previous year.

Compensation breakdown

Bonus$7,500
Non-Equity Incentive Plan$461,108
Salary$365,959
Stock Awards$2,317,820
Other$22,251
Total$3,174,638

Balo received $2.3M in stock awards, accounting for 73% of the total pay in 2018.

Balo also received $7.5K in bonus, $461.1K in non-equity incentive plan, $366K in salary and $22.3K in other compensation.

Rankings

In 2018, Andrew Balo's compensation ranked 3,636th out of 14,244 executives tracked by ExecPay. In other words, Balo earned more than 74.5% of executives.

ClassificationRankingPercentile
All
3,636
out of 14,244
75th
Division
Manufacturing
1,348
out of 5,758
77th
Major group
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks
162
out of 849
81st
Industry group
Surgical, Medical, And Dental Instruments And Supplies
88
out of 547
84th
Industry
Surgical and Medical Instruments and Apparatus
56
out of 348
84th

Pay ratio

Andrew Balo's Pay$3,174,638
Median Employee's Pay$80,723
Pay Ratio

39

to 1

In 2018, the annual total compensation of Andrew Balo was $3,174,638.

The annual total compensation of the median employee at DexCom was $80,723.

The ratio of Andrew Balo's pay to the pay of median employee was therefore 39 to one.

Source: SEC filing on April 19, 2019.

Balo's colleagues

We found four more compensation records of executives who worked with Andrew Balo at DexCom in 2018.

2018

Kevin Sayer

DexCom

Chief Executive Officer

2018

Quentin Blackford

DexCom

Chief Financial Officer

2018

Richard Doubleday

DexCom

EVP, Chief Commercial Officer

2018

Steven Pacelli

DexCom

EVP, Strategy and Corporate Development

News

You may also like